Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000483036 | SCV000566513 | uncertain significance | not provided | 2019-09-20 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge; No data available from control populations to assess the frequency of this variant; Results in the change of an Alanine to a Threonine (GCC>ACC) in exon 1 of the p14-ARF protein. |
Labcorp Genetics |
RCV000547575 | SCV000637431 | uncertain significance | Familial melanoma | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002356769 | SCV002655996 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-26 | criteria provided, single submitter | clinical testing | The p.A41T variant (also known as c.121G>A), located in coding exon 1 of the CDKN2A (p14ARF) gene, results from a G to A substitution at nucleotide position 121. The alanine at codon 41 is replaced by threonine, an amino acid with similar properties. This amino acid position is well conserved on limited sequence alignment. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |